The Tumor Microenvironment is Complex. Your Assays Shouldn’t Be.
The Tumor Microenvironment is Complex.
Your Assays Shouldn’t Be.
Whole Slide Imaging
Visualize all cells
Characterize each cell type
Determine cell interaction
InSituPlex® Technology - The Ultivue Difference
A simplified workflow that utilizes your existing histology equipment, scanners and image analysis software
Same Day Results
High throughput assays for fast staining, scanning, and image analysis
Investigate complex phenotypes through coexpression of markers on single cells
Identify high and low abundance markers
Services and Programs
CRO Services + Biomarker Programs
With speed and flexibility at heart, both our Staining and Imaging Services and our Biomarker Programs offer highly customizable panels to accelerate your research.
InSituPlex in Action
InSituPlex used to assess immune checkpoint inhibitor targeted CD8 activation and tumor co-localization
Deep spatial immuno-profiling through high biomarker colocalization in FFPE tumor tissue samples
Ultivue and Indivumed partner for research and drug development in personalized oncology
Ultivue and OracleBio partner to help advance personalized tumor characterization and clinical oncology research using multiplex immunofluorescence
CAMBRIDGE, Mass, July 22, 2020 – –Ultivue, Inc. today announced a collaborative partnership with OracleBio to help further insights and advance personalized tumor characterization in translational and clinical oncology research and drug development using multiplex immunofluorescence staining and imaging.
Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services
Kassel, Germany and Cambridge, MA, USA November 7, 2019 – Targos Molecular Pathology GmbH, a market leader in clinical biomarker services announced today a technology partnership with Ultivue, the innovation leader in multiplex tissue biomarker assays.